Latest News & Features
Americas
Litigator brings extensive courtroom experience and advises clients on how to navigate disputes through federal courts, state courts, and arbitrations. 13 August 2024
Americas
Swiss biopharma took preemptive legal action against US rival after learning it would be subject to “aggressive” enforcement over therapy | Technology at heart of case treats disruptions to healthy bacterial organisms in human intestinal tract. 13 August 2024
Americas
A Delaware jury found AstraZeneca liable for induced infringement of a cancer treatment in May | Pharma company levelled allegations of "unclean hands" and "patent misuse" at Pfizer unit. 8 August 2024
Careers
The firm adds three partners to its New York office | Expansion brings a combined 60 years of experience | Hires experienced in high-stakes patent disputes involving biologics, small-molecule drugs, and medical devices. 8 August 2024
Americas
District court partially grants Ultrahuman Healthcare's motion to stay patent litigation with Oura Health, pending an ITC investigation | Court's order pauses several patent claims | Decision allows Oura's copyright allegations to proceed independently. 6 August 2024
Americas
Big pharma subsidiary and Japanese collaborator allege infringement of blockbuster drug product | $1.2 billion treatment developed by University of California. 6 August 2024
Americas
Pharma company argues that affirming lower court’s decision would shrink Orange Book “dramatically” | District court found Teva’s patents do not claim the drug product for which they are listed. 1 August 2024
Americas
Being a lawyer with ADHD is far from easy due to widespread misconceptions about the condition but there are ways to offer support, says Lisa Mueller of Casimir Jones. 1 August 2024
Americas
Senior partner in IP department will become co-managing partner | Foley Hoag elected three other members of five-strong executive committee this year 1 August 2024
Americas
Biopharmaceutical company insisted its cancer treatment should be considered a biologic | Panel finds “unfairly reductive” arguments “just don’t work” | FDA correct to reject Ipsen based on faulty scientific expertise. 30 July 2024